John Fanikos Praises Nathan Connell’s Efforts on Hemophilia Gene Therapy in Boston
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared a post on LinkedIn:
“Hemophilia historically has been seen as a ‘royal disease’ because of its occurrence in the royal families of Spain, Germany and Russia.
Today it is known as a genetic disorder where bleeding occurs because of low levels of blood clotting Factor 8 (VIII) or Factor 9 (IX). As simple as a missing gene on a chromosome that provides the blueprint for the protein Factor.
Enter gene therapy.
Kudos to Dr Nathan Connell, who worked feverishly to bring this treatment to the Boston area.
You can hear the treatment results of his first patient on the CBS news and follow his expertise at the Vasculearn Network”
Nathan Connell’s first patient results featured on CBS News.
Follow his expertise on the Vasculearn Network.
Stay informed with Hemostasis Today.
-
May 26, 2026, 13:21Isabelle Mahé: Frailty Does Not Mean Less Anticoagulation
-
May 26, 2026, 12:32Behçet Syndrome and Thrombosis: When Inflammation Becomes a Clot
-
May 26, 2026, 12:29Priya Prasad: When Blood Becomes the Battlefield – Transfusion Medicine Saves Lives
-
May 26, 2026, 12:21Mavis Agnes Kisakye: Uganda at the WFH Regional Conference on Blood Disorders
-
May 26, 2026, 12:19Megan Adediran: Giving Hope to People Living with Bleeding Disorders
-
May 26, 2026, 11:36Abid Ur Rahman: Understanding the Coagulation Cascade and Hemostasis
-
May 26, 2026, 11:35Isaac Okello: The Real Sickle Cell Crisis Is Not Only the Disease Itself
-
May 26, 2026, 11:34Ziad Omar: PTT and aPTT Testing – Reading the Intristic Pathway of Coagulation
-
May 26, 2026, 11:33Megan Griffiths: Advancing the Understanding of Risk and Outcomes in Pulmonary Hypertension